Phase III RASolute 302: Daraxonrasib Across Key Subgroups in Metastatic Pancreatic Cancer At the ESMO Congress 2026, Zev A. Wainberg presented additional exploratory subgroup analyses from the Phase III RASolute 302 trial (LBA82), evaluating daraxonrasib versus standard-of-care chemotherapy in previously treated metastatic pancreatic ductal adenocarcinoma (mPDAC). Key findings: 🔹 Overall OS (primary analysis): 13.2 vs 6.7 months (HR 0.40; 95% CI 0.30–0.53). 🔹 RAS genotype: OS hazard ratios numerically favoured daraxonrasib across evaluated subgroups, including patients without an identified tumour RAS mutation. 🔹 Preselected chemotherapy regimens: OS HRs ranged from 0.32 to 0.46. 🔹 Prior treatment setting: OS HR was 0.36 (95% CI 0.17–0.75) for early metastatic recurrence following perioperative therapy and 0.43 (95% CI 0.32–0.58) after one prior line of metastatic therapy. Takeaway: Exploratory analyses showed directionally consistent OS outcomes favouring daraxonrasib across clinically relevant subgroups. Findings in smaller mutation-defined subgroups require cautious interpretation due to limited sample sizes and wide confidence intervals. @MiteshBorad @FilippoPietran4 @ChiaraCrem1 @oncodaily @myESMO oncodaily.com/gastrointestin… #ESMO2026 #RASolute302 #OncoDaily #ESMO26